|
|
|
|
| Symbol(s): |
CPD |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
3CARA has a current Overall Rating of C (Neutral). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| 3CARA has a current Overall Rating of C (Neutral). Power Rating (72) is high; appreciation potential (42) is neutral. Relative to the S&P 500 Composite, Caraco Pharmaceutical Labs has slightly more Value than Growth characteristics -- its appeal is likely to be to Capital Gain-oriented investors. CPD is of the highest investment quality. 3CARA's current technical position is very strong. 3CARA's Power Rating is 72. Earnings estimate behavior for 3CARA has been slightly favorable...
| | |
|
|
